The ACEi SwitchBack Study
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- proportion of patients on ARB who are switched back to ACEi and\ who tolerate ACEi
Study Overview
Brief Summary
ACE inhibitors have been studied extensively in the treatment of heart failure and have been shown to be beneficial in all its stages. Studies with the use of angiotensin receptor blockers (ARBs) in chronic heart failure have not shown equivalent results. Many patients are on an ARB for a variety of reasons. Some of these may have had cough as a symptom of heart failure and not due to medication side effect. According to guidelines, angiotensin converting enzyme inhibitors (ACEi) are still first-line therapy in the treatment of heart failure. As ACEi have been extensively studied showing improvement in morbidity and mortality all patients should be on this treatment unless absolutely contraindicated.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •heart failure patients who have indications for ACEi but are currently on ARBs with no absolute contraindications to ACEi
- •patients with an ejection fraction of < or = 35% verified in the last 12 months by echo, angio, or nuc med who are NYHA class I to IV and followed in a heart failure clinic for three months
- •on beta-blockers, unless contra-indicated
- •stable on current meds for 3 months (except dose of diuretics)
- •able to give informed consent
Exclusion Criteria
- •documented angioedema/anaphylaxis with prior ACEi use
- •documented worsening renal failure, hyperkalemia, cough and gastrointestinal symptoms that are definitely believed to be due to ACEi
- •potassium >5.0 mmol/L
Outcomes
Primary Outcomes
proportion of patients on ARB who are switched back to ACEi and\ who tolerate ACEi
Time Frame: 6 months
Patients with heart failure who are on ARB who do not clear contra-indication to ACEi will be switched to an ACei. their tolrance to this will be evaluated
Secondary Outcomes
No secondary outcomes reported